Research programme: chronic obstructive pulmonary disease therapeutics - LTT Bio-Pharma

Drug Profile

Research programme: chronic obstructive pulmonary disease therapeutics - LTT Bio-Pharma

Alternative Names: LT-0302; mepenzolate bromide - LTT Bio-Pharma

Latest Information Update: 15 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LTT Bio-Pharma
  • Class Anti-inflammatories; Bronchodilators; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Aug 2015 LTT Bio-Pharma has international patent protection for COPD therapeutics
  • 13 Aug 2015 Early research in Chronic obstructive pulmonary disease in Japan before august 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top